Latest news with #YigalNochomovitz
Business Insider
2 days ago
- Business
- Business Insider
Citi Sticks to Its Buy Rating for LENZ Therapeutics (LENZ)
In a report released today, Yigal Nochomovitz from Citi maintained a Buy rating on LENZ Therapeutics (LENZ – Research Report), with a price target of $45.00. The company's shares closed today at $31.22. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Nochomovitz is a 4-star analyst with an average return of 3.5% and a 38.98% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Summit Therapeutics, and Arvinas Holding Company. LENZ Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $47.43.
Business Insider
2 days ago
- Business
- Business Insider
Citi Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Citi analyst Yigal Nochomovitz maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) today and set a price target of $47.00. The company's shares closed today at $12.54. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Nochomovitz is a 4-star analyst with an average return of 3.5% and a 38.98% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Summit Therapeutics, and Arvinas Holding Company. Arcturus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $51.63.
Yahoo
28-03-2025
- Business
- Yahoo
Why Summit Therapeutics Stock Slipped Today
Summit Therapeutics (NASDAQ: SMMT) stock did better than a lot of other equities during an otherwise forgettable trading session on Wednesday. In contrast to other titles that fell notably, Summit more or less kept pace with the S&P 500 (SNPINDEX: ^GSPC), managing to dip by a relatively modest 2.25% in price. Some investors, at least, were cheered by an analyst's recommendation upgrade on the stock. Well before market open, Citigroup pundit Yigal Nochomovitz changed his recommendation on Summit's shares to buy from neutral. Accompanying this was a generous price target increase; the analyst's fair value assessment is now $35 per share, where formerly it stood at $23. According to reports, Nochomovitz wrote that his move was based on a concentrated analysis of the prospects for ivonescimab. This is a rather promising cancer drug Summit has licensed from Chinese peer Akeso. The pundit feels that the coming readout of the medication's Harmoni-2 late-stage clinical trial has a 70% chance of indicating a favorable result with overall survival rates. Ivonescimab has already attracted much notice after Akeso divulged the results of a clinical trial pitting it against 2024's top-selling drug, Merck's blockbuster Keytruda, for the treatment of non-small cell lung cancer (NSCLC). The recommendation upgrade is certainly heartening, but there are two factors mitigating this just now. First, as ever in the biotech world, a company's success depends on it bringing medications to market; ivonescimab's promise is only that at the moment, and much work still needs to be done before it can win potentially win approval from top regulators (let alone succeed as a commercialized product). Second, there is still much uncertainty swirling around the tariffs President Trump aims to impose on certain trade partners next week. He has specifically mentioned the pharmaceutical sector as a target for such levies; however, his administration hasn't yet proffered many details of the extra costs importers will have to pay. Before you buy stock in Summit Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $739,720!* Now, it's worth noting Stock Advisor's total average return is 870% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of March 24, 2025 Citigroup is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Summit Therapeutics. The Motley Fool has a disclosure policy. Why Summit Therapeutics Stock Slipped Today was originally published by The Motley Fool Sign in to access your portfolio
